🇺🇸

IPO Capital Markets

US SEC Filing Intelligence · 150 digests

New to these filings? Learn what an S-1 is · what an S-3 shelf registration is

· daily

US IPO Pipeline SEC S-1 Filings — October 09, 2026

Across the 11 filings for the IPO Pipeline stream (all dated 2026-10-09 or the immediately preceding window), the dominant theme is capital formation under strain: a small-cap IPO (Simwon America), a going-concern biotech resale registration (GT Biopharma), a capital-hungry bridge-loan-funded issuer (Cyabra), a distressed warrant overhang (BIO-key), and a convertible-debt-laden filer (Specificity) all surface alongside a clinical-stage biotech IPO (Aspen Neuroscience, Bambusa) and two SPAC or M&A-driven listings (Plus Automation via Texas Ventures III; Vireo/Planet 13 and DTI/Saltire). Period-over-period comparison data is thin across this batch: several excerpts omit revenue, margin, or net income figures entirely (Simwon, Aspen, Patriot Mobile, Specificity, Plus Automation), so cross-company growth or margin comparisons cannot be made reliably and should be treated as a data gap rather than a signal. Where quantitative anchors exist, they point to dilution and financing pressure rather than growth: GT Biopharma's 1-for-25 reverse split cut shares outstanding from 45.1M to 1.8M, BIO-key's inducement repriced warrants from $10.20 to $4.06, and Cyabra is explicitly reliant on bridge and convertible financing. Insider signals are largely absent from the excerpts, so management conviction cannot be assessed from this batch. The most market-relevant developments are the Vireo/Planet 13 merger (materiality 9/10), the Plus Automation SPAC combination with redemption scenarios, and the DTI acquisition requiring a Nasdaq 5635(a) shareholder vote. Net implication: the IPO window is open for selectively credible names, but this batch skews toward financing-dependent issuers where dilution risk outweighs the offering narrative.

11 high priority 11 total filings
· daily

US IPO Pipeline SEC S-1 Filings — October 08, 2026

Two SEC filings dated October 8, 2026 fall into the IPO Pipeline / new registrations stream: an S-4 from Boundless Bio, Inc. tied to a pending merger with Seraphа Bio, Inc. (signed June 22, 2026), and an S-4 from Columbus Circle Capital Corp II (now Inflection Point Acquisition Corp. VII) for a proposed SPAC business combination with Elroy Air, Inc., an autonomous aircraft developer. Both filings are neutral in sentiment and rated 7/10 materiality, but the supplied excerpts are largely XBRL tags and header data, so the enriched period-over-period, forward-looking, insider, and capital allocation fields contain no legible dollar amounts, growth rates, or guidance figures. No cross-company margin, growth, or insider patterns can be quantified from this set. The actionable takeaway is that both transactions are registration-stage: deal economics, exchange ratios, pro forma results and shareholder vote timing must be confirmed in the full prospectuses before any position is taken. The most material development is the emergence of a de-SPAC pathway into a capital-intensive hardware sector (autonomous aircraft), which warrants monitoring of redemption levels and funding adequacy.

2 high priority 2 total filings
· daily

US IPO Pipeline SEC S-1 Filings — October 07, 2026

The IPO pipeline is active with three S-1 filings on October 7, 2026, spanning industrial automation, medical devices, and pre-clinical biotech. FireFly Automatix seeks to go public despite a high-risk profile of net losses and significant debt, including multiple 11% and 15% debentures. Centinel Spine offers a mixed outlook with no near-term dividend policy and substantial dilution risks, but benefits from a 180-day lock-up period for insiders. Salarius Pharmaceuticals (Decoy Therapeutics) is a pre-clinical biotech with limited cash ($8.0M) and no revenue, but recently raised $3.85M through warrant exercises, signaling a focus on near-term survival over growth. Across filings, period-over-period data would highlight cash burn rates, but only Salarius provides forward-looking cash runway; all three companies lack product revenue, underscoring a speculative IPO environment. No insider trading activity was reported, limiting conviction signals. The pipeline is dominated by high-risk, pre-revenue companies, suggesting investor caution is warranted.

3 high priority 3 total filings
· daily

US IPO Pipeline SEC S-1 Filings — October 06, 2026

The IPO pipeline is rapidly diversifying across sectors, with two biotech/pre-revenue debuts (Actuate Therapeutics, Pluri), a blank-check vehicle (Tang Capital Acquisition), a profitable AI-services firm with growing losses (Fusemachines), and an innovative crypto-ETF (Winklevoss Zcash ETF) – indicating a market that is accepting both high-risk, pre-commercial science and novel digital assets. A clear period-over-period red flag emerges: Fusemachines’ net loss nearly doubled from $4.4M in 2024 to $7.7M in 2025, even as it struggles with revenue concentration (58% from three customers), presenting a classic “growth at any cost” cautionary tale. The biotech cohort shows mixed signals—Actuate has zero revenue and negative working capital (only $943K), while Pluri’s filing is a secondary resale (no new capital for operations), both suggesting fragile cash positions. The Winklevoss trust, while chasing a niche crypto, carries a distinct operational risk from a recent ~50% price crash following a security vulnerability and the departure of the core development team—highlighting a sector-specific governance gap. Taken together, this pipeline reflects a risk-on environment where investors must dissect revenue quality (Fusemachines), cash runway (Actuate), security event risks (Zcash), and sponsor skin-in-the-game (Tang Capital’s 67% stake). The key portfolio-level pattern is a bifurcation: speculative biotech and crypto offerings rush to list under the JOBS Act, while more established AI-services firms like Fusemachines face increasing scrutiny over burn rates.

5 high priority 5 total filings
· daily

US IPO Pipeline SEC S-1 Filings — October 05, 2026

The IPO pipeline for October 5, 2026, is dominated by SPAC-related filings (New Iceland Arctic, Quantum Space, Tigerless Health, Welsbach Technology Metals) and two traditional IPOs (Lycia Therapeutics, Propanc Biopharma), alongside a bank merger S-4 (Equity Bancshares). A key theme is the high risk of value destruction for public shareholders in SPAC structures: Tigerless Health has no maximum redemption threshold and a dual-class structure giving 100% voting control to one insider, while New Iceland Arctic shows negative net tangible book value per share under redemption scenarios. Period-over-period data reveals deteriorating financials at Lincoln Bancorp (net loss swung to -$13.19M from -$1.207M YoY) and heavy reliance on dilutive debt at Propanc Biopharma. Lycia Therapeutics stands out as a pre-revenue biotech with promising Phase 1 data for its lead candidate LCA-0061, but no pricing details yet. The overall pipeline signals a cautious market with significant governance and financial risks embedded in the SPAC structures, while traditional IPOs remain early-stage and speculative.

7 high priority 7 total filings
· daily

US IPO Pipeline SEC S-1 Filings — October 02, 2026

On October 2, 2026, nine SEC filings revealed a dense IPO pipeline, dominated by six initial public offerings and registration statements, alongside three merger-related S-4 filings. The day’s filings signal a surge in capital formation, particularly among clinical-stage biotech (HCW Biologics, Sunshine Biopharma), early-stage technology (Vertical Data), and specialty healthcare (BioStem Technologies) companies, many of which carry high risk due to pre-revenue status, accumulated deficits, or dilution-heavy capital structures. Aggregate period-over-period data shows that the combined pro forma entity from the John Marshall Bancorp merger would have generated $74.2M in net interest income (up 111% from JMSB standalone), while HCW Biologics remains pre-revenue with an accumulated deficit of -$168.2M. Key patterns include a notable reliance on non-traditional listing methods (direct listing for Georgia Banking Co.), heavily dilutive warrant structures, and distinct geographic concentration in the mid-Atlantic and Hong Kong-based blank check SPAC. The absence of meaningful insider trading activity in these pre-public companies limits conviction signals, but forward-looking disclosures point to material catalysts—including a Phase 1 readout and a critical Nasdaq compliance decision—that frame near-term risk/reward.

9 high priority 9 total filings
· daily

US IPO Pipeline SEC S-1 Filings — October 01, 2026

The IPO pipeline for October 1, 2026, is dominated by SPAC and blank check activity, with REEcycle's $400M business combination and POP Global's $100M IPO highlighting continued appetite for speculative vehicles despite regulatory scrutiny. Uranium Royalty Corp.'s massive 226.7M share resale registration signals potential overhang, while WhiteHawk's S-1 reveals accounting restatements and complex capital structure. VSEE Health's delisting and reverse split represent a distressed situation with high risk. First Internet Bancorp's exchange offer is a routine debt transaction with minimal market impact. The pipeline shows a bifurcation between high-quality resource plays (Uranium Royalty) and speculative SPACs/distressed issuers, with no traditional operating company IPOs in this cohort.

6 high priority 6 total filings
· daily

US IPO Pipeline SEC S-1 Filings — September 30, 2026

The IPO/follow-on pipeline for the period shows a bifurcated market: two blank-check companies (BHAV, Spark I) are pursuing traditional SPAC capital raises and de-SPAC transactions, while two operating companies (GEN Restaurant Group, Trump Media) are executing highly dilutive and strategically aggressive capital raises. A dominant theme is extreme dilution risk: GEN Restaurant's registration covers 205.5% of shares outstanding, and Trump Media's merger requires a doubling of authorized shares. The SPACs show no revenue and ongoing net losses, with Spark I reporting a $0.5M net loss for both the six-month 2026 and full-year 2025 periods, indicating stable but persistent cash burn. Insider activity is limited but notable: the Trump Revocable Trust's agreement to vote all shares in favor of the TAE merger signals strong insider alignment. Forward-looking catalysts are clustered around shareholder meetings and the effectiveness of registration statements, with the TMTG special meeting and GENK's purchase agreement effective date being key near-term events. Overall, the pipeline is dominated by speculative, event-driven situations with high dilution and binary outcomes, rather than traditional growth IPOs.

4 high priority 4 total filings
· daily

US IPO Pipeline SEC S-1 Filings — September 29, 2026

The sole filing in this IPO Pipeline digest is from MNBS Acquisition Corp., a special purpose acquisition company (SPAC) seeking to raise $75 million through an initial public offering. As a blank-check company with no operating history or identified target, the filing represents a speculative capital-raising vehicle rather than an operating business. The offering structure includes units composed of shares, warrants, and rights, with standard SPAC terms including a 12-month deadline to complete a business combination. The neutral sentiment and lack of period-over-period comparisons, insider activity, or forward-looking guidance reflect the pre-operational nature of this entity. The key market implication is that SPAC IPOs continue to surface in the US market, though investor appetite for such vehicles remains cautious given historical redemption rates and regulatory scrutiny. The filing provides no actionable financial trends or management signals, as it is a blank-check company with no prior financial performance.

1 high priority 1 total filings
· daily

US IPO Pipeline SEC S-1 Filings — September 28, 2026

The IPO pipeline on September 28, 2026, is dominated by SPAC activity, with three blank-check companies (Silicon Valley Acquisition Corp., Calm Seas Acquisition Corp., and Orange Street Acquisition Corp.) filing registration statements alongside two traditional operating companies (General Enterprise Ventures and HMH Holding). A key portfolio-level trend is the divergence in financial health: while the SPACs show no revenue and increasing losses (SVAQ's net loss widened 25% YoY to $1.23M), HMH Holding reveals a complete write-down of a $0 seller's receivable and rising unallocated costs ($8.9M to $10.8M YoY). General Enterprise Ventures carries significant debt with convertible notes at fixed prices ($2.40 and $2.16 per share), creating potential dilution. The most critical development is the SVAQ/EigenQ business combination, which brings a revenue-generating target into a SPAC structure. No insider trading activity was reported across any filing, limiting conviction signals. The pipeline suggests a market favoring SPAC structures for bringing companies public, but the underlying financials of the operating companies warrant caution due to deteriorating trends and contingent liabilities.

5 high priority 5 total filings
· daily

US IPO Pipeline SEC S-1 Filings — September 25, 2026

The IPO pipeline for September 25, 2026, reveals a bifurcated market: one traditional operating company (Interpace Biosciences) seeking to raise capital amid severe operational distress, one blank-check company (TCGX Acquisition Corp. II) launching a standard SPAC IPO, and one business combination filing (Snowdrift Parent Corp / Chemomab Therapeutics) reflecting the ongoing de-SPAC trend. Period-over-period trends are limited as these are initial registration statements, but the filings collectively signal a cautious but active market for equity capital formation. Interpace's S-1 highlights a company in crisis—post-Nasdaq delisting, reliant on a single customer, and with no near-term product pipeline—while TCGX's SPAC IPO represents a pure-play bet on management's ability to find a target within 24 months. The Chemomab/Snowdrift combination underscores persistent capital needs in the biotech sector, with Chemomab showing continued operating losses and reliance on multiple financing rounds. The most critical development is Interpace's attempt to go public despite severe headwinds, which may test investor appetite for high-risk, micro-cap diagnostics. Portfolio-level patterns include a lack of insider buying in any filing, signaling management caution, and a reliance on external capital (SPACs, follow-ons) rather than organic growth.

3 high priority 3 total filings
· daily

US IPO Pipeline SEC S-1 Filings — September 24, 2026

The IPO pipeline is active with three new filings this week, spanning a REIT merger, a life sciences SPAC, and a clinical-stage biotech IPO, alongside a previously covered bank acquisition. The most material development is City Therapeutics' IPO filing, which reveals a stark contrast between surging collaboration revenue (up 128% YoY) and rapidly widening net losses (from $27.8M to $58.5M in 2025), driven by a 90% surge in R&D spending—a classic high-risk, high-reward biotech profile. The Independence Realty Trust/CSR merger S-4 highlights a fixed-exchange-ratio structure that exposes CSR shareholders to market risk, with a hard deadline of June 30, 2027. The Frazier Life Sciences SPAC IPO is a standard blank-check offering with $75M in trust, while the First Bancorp acquisition of First Carolina Bancshares shows a positive sentiment with a detailed stock-and-cash consideration structure. A key portfolio-level pattern is the divergence in capital intensity: biotech is burning cash aggressively for growth, while financial and REIT sectors are pursuing consolidation with defined deal mechanics.

4 high priority 4 total filings
· daily

US IPO Pipeline SEC S-1 Filings — September 23, 2026

The single filing in this IPO Pipeline digest—Patrick Industries Inc.'s S-4 registration for its merger with LCI Industries—represents a transformative event in the outdoor recreation and housing components sector, though it is a business combination rather than a traditional IPO. The deal creates a premier component solutions provider with a fixed exchange ratio of 1.2440 Patrick shares per LCI share, implying a valuation that fluctuates with Patrick's stock price. No period-over-period financial trends, insider trading, capital allocation changes, or forward-looking guidance are disclosed in this filing, limiting the depth of quantitative trend analysis. The neutral sentiment and high materiality score (9/10) reflect the deal's structural significance but lack of immediate directional market signal. The combined entity's shareholder composition (52% Patrick, 48% LCI) suggests a near-equal merger, with potential for post-merger synergies and name change catalysts. Investors should monitor shareholder votes and any subsequent financial disclosures for valuation insights.

1 high priority 1 total filings
· daily

US IPO Pipeline SEC S-1 Filings — September 22, 2026

The IPO pipeline on September 22, 2026, reveals a bifurcated market with two traditional IPOs (Glow Holdings, NewHydrogen) and two reverse-merger/SPAC-like transactions (Werewolf/Ambros, Boxlight resale). The traditional IPOs are micro-cap, pre-revenue companies with no minimum offering amounts, signaling a 'testing the waters' approach by issuers in a cautious market. The reverse mergers and resale filings indicate a strong preference for alternative public market access, with Werewolf/Ambros representing a $500M+ combination that will effectively replace the existing public entity. Period-over-period data is limited as all filings are initial registrations, but the absence of revenue for NewHydrogen and Glow's negative book value highlight the early-stage nature of the pipeline. The most critical development is the Werewolf-Ambros merger, which ascribes a 10.5x valuation premium to Ambros over Werewolf, creating a significant arbitrage opportunity for existing HOWL shareholders. Insider activity is absent across all filings, but capital allocation patterns—Glow's $100K software spend vs. Boxlight's dilutive financing—reveal divergent strategies. The pipeline is dominated by high-risk, high-dilution structures, suggesting a market environment where only desperate or opportunistic issuers are accessing public markets.

4 high priority 4 total filings
· daily

US IPO Pipeline SEC S-1 Filings — September 21, 2026

The IPO pipeline on September 21, 2026, features two distinct new registrations: Iambic Therapeutics, an AI-driven biopharmaceutical company, and Silicon Valley Acquisition Corp. II, a blank-check SPAC. Both filings are at the initial S-1 stage with no disclosed pricing or share counts, indicating early-stage capital formation. The biotech IPO signals continued investor appetite for AI-enabled drug discovery platforms, while the SPAC filing suggests renewed activity in the blank-check space despite regulatory headwinds. No period-over-period comparisons, insider activity, or forward-looking guidance are available from these initial filings, limiting trend analysis but highlighting the nascent nature of these offerings. The lack of financial metrics or operational history for either company underscores the speculative nature of early-stage IPO investments. Market implications center on the potential for Iambic's registrational trial catalyst in 2027 and SVAC II's ability to execute a de-SPAC transaction in a challenging market.

2 high priority 2 total filings
· daily

US IPO Pipeline SEC S-1 Filings — September 18, 2026

The IPO pipeline is experiencing a surge of activity with 11 filings on September 18, 2026, spanning biotech, SPAC, technology, and industrial sectors. A dominant theme is the influx of clinical-stage biopharmaceutical companies (5 of 11 filings) all in pre-revenue stages with widening losses, signaling high cash burn and dilution risk. The SPAC merger between Kensington Capital and Nth Cycle highlights continued de-SPAC activity, while Fold Holdings' S-1 reveals a $25M equity line with insider conflict concerns. Period-over-period data shows deteriorating financial health across pre-revenue biotechs, with aggregate net losses increasing 26.8% YoY for Lakewood-Amedex and 33.3% for BioStem. However, the presence of a non-binding interest from Eli Lilly in TRex Bio's IPO provides a bullish anchor for the biotech cohort. The pipeline is heavily weighted toward early-stage, high-risk companies with going concern uncertainties, but the diversity of sectors—from critical minerals (SmartKem/Ferrox) to AI infrastructure (Nscale/Arkon Energy)—offers selective alpha opportunities for investors willing to navigate the risk.

11 high priority 11 total filings
· daily

US IPO Pipeline SEC S-1 Filings — September 17, 2026

The sole filing in this IPO Pipeline digest is GeoVax Labs, Inc.'s S-1 registration statement, which reveals a company in severe financial distress rather than a traditional growth-oriented IPO. The filing is a desperate capital raise attempt amid a Nasdaq delisting threat, with a hearing scheduled for October 13, 2026. Period-over-period data shows a deteriorating equity position, and the company's prior reverse stock split (1-for-25) has eliminated its standard cure period. The negative sentiment and 10/10 materiality score underscore an existential risk for existing shareholders. No bullish signals or growth catalysts are present, making this a high-risk, speculative filing with no clear path to a successful public offering or continued listing.

1 high priority 1 total filings
· daily

US IPO Pipeline SEC S-1 Filings — September 16, 2026

The single filing in this IPO Pipeline digest is a SPAC (Special Purpose Acquisition Company) S-1 registration from Lower Cross Acquisitions Corp, which signals a continued, albeit cautious, appetite for blank-check vehicles in the current market. The filing's negative sentiment and high-risk disclosures highlight a persistent structural concern for SPAC investors: the potential for significant dilution and the lack of a redemption threshold. While this is an isolated filing, it serves as a critical reminder of the specific risks inherent in SPAC IPOs versus traditional operating company listings. The absence of any operating company IPOs or follow-on offerings in this period suggests a quiet window for new issuances, possibly due to market volatility or geopolitical uncertainty. The key takeaway for investors is to approach this SPAC with extreme caution, focusing on the sponsor's track record and the terms of the trust, as the structure heavily favors the sponsor over public shareholders.

1 high priority 1 total filings
· daily

US IPO Pipeline SEC S-1 Filings — September 15, 2026

The IPO pipeline is active on September 15, 2026, with six filings spanning blank-check companies, a fintech firm, a REIT merger, a digital asset play, and a distressed operating company. The most notable quantitative trends include a heavy concentration of SPACs (two out of six filings), each offering 15 million units at $10.00—raising $150 million each—suggesting a revival in blank-check vehicles after a quiet period. FDCTECH, INC. stands out as the only filing with period-over-period comparisons, revealing a 3% YoY revenue decline in H1 2026 ($43.1M to $41,8M) and stagnant profitability, though paired with heavy tech service investments. The Hyperliquid Strategies S-1 reflects a novel structure—acquiring HYPE tokens via a reverse merger—while Creatd’s registration is marked by deep financial distress, with repeated losses on debt conversions (e.g., 80% losses on note settlements) and a rescission of equity issuances. The MITT/CHMI merger via S-4 is a sector consolidation play, combining two residential REITs. Key market implication: investors should differentiate between high-risk operating companies (Creatd) and asset-backed SPACs (SPACCircle, Oceanhawk), while watching for excessive dilution in token/SPEC offerings. No insider trading data was available across filings, and forward-looking guidance was minimal beyond SPAC business combination timelines.

6 high priority 6 total filings
· daily

US IPO Pipeline SEC S-1 Filings — September 14, 2026

The IPO pipeline is active with three new S-1/S-4 filings on September 14, 2026, signaling sustained issuance momentum despite mixed market conditions. MiniMed Group's spin-off from Medtronic, completed in March 2026, stands out with strong 11.5% YoY revenue growth to $3.1B and 14.5% net income expansion, though its CGM segment declined 2.1% YoY, creating a nuanced growth story. Syra Health Corp's IPO filing reveals a company with accumulated losses and reliance on related-party transactions, indicating early-stage risk. MFB Bancorp's mutual-to-stock conversion offers a traditional small-cap bank IPO at $10/share with a minimum subscription threshold. Air Lease Corp's $4.0B exchange offer post-merger highlights significant debt management activity in the aircraft leasing sector. Key period-over-period trends show revenue growth across healthcare (MiniMed +11.5%) but margin pressures in smaller issuers. The most critical development is the diversity of capital-raising structures—spin-off, traditional IPO, mutual conversion, and debt exchange—reflecting varied market access strategies.

4 high priority 4 total filings